Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T21:07:34.789Z.
Calculation as of: 2026-10-06T21:07:34.789Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a8ac43d83dffe882666147bba78c75a2aa07862642b14baa2694f769a95b4c3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$5.21M
PB Ratio
1.07
TTM Avg
28.43
3Y Avg
28.43
5Y Avg
28.43
Market Cap
$5.24M
PB Ratio
0.95
TTM Avg
0.99
3Y Avg
1.17
5Y Avg
4.93
Market Cap
$4.97M
PB Ratio
16.53
TTM Avg
6.60
3Y Avg
6.60
5Y Avg
6.60
Market Cap
$5.32M
PB Ratio
0.56
TTM Avg
0.66
3Y Avg
0.66
5Y Avg
0.66
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.12M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | 0.90 | 2.38 | 1.71 | 5.62 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | 1.07 | 28.43 | 28.43 | 28.43 |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | 3.28 | 2.45 | 1.80 | 1.25 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | 0.95 | 0.99 | 1.17 | 4.93 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | 16.53 | 6.60 | 6.60 | 6.60 |
| Soligenix, Inc. (SNGX)vs › | $5.31M | 0.80 | 1.25 | 1.71 | 3.44 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | 0.56 | 0.66 | 0.66 | 0.66 |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | 1.13 | 3.18 | 3.59 | 2.88 |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | 0.80 | 1.05 | 0.86 | 0.74 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
